Sept 27 (Reuters) - The U.S. health regulator's advisers on Wednesday voted against BrainStorm Cell Therapeutics' therapy for patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli and Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.456 USD | -2.36% | +20.00% | +67.03% |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 | CI |
Apr. 17 | Brainstorm Cell Therapeutics Inc. Announces Management Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.03% | 31.16M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- BCLI Stock
- News Brainstorm Cell Therapeutics Inc.
- US FDA panel votes against BrainStorm's ALS therapy